View in EDS HTML Full Text PDF Full Text

Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study.

Saved in:
Bibliographic Details
Title: Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study.
Authors: Comi G (AUTHOR), Filippi M (AUTHOR), Barkhof F (AUTHOR), Durelli L (AUTHOR), Edan G (AUTHOR), Fernández O (AUTHOR), Hartung H (AUTHOR), Seeldrayers P (AUTHOR), Sørensen PS (AUTHOR), Rovaris M (AUTHOR), Martinelli V (AUTHOR), Hommes OR (AUTHOR), Early Treatment of Multiple Sclerosis Study Group (CORPORATE AUTHOR), Comi, G (AUTHOR), Filippi, M (AUTHOR), Barkhof, F (AUTHOR), Durelli, L (AUTHOR), Edan, G (AUTHOR), Fernández, O (AUTHOR), Hartung, H (AUTHOR)
Source: Lancet. 5/19/2001, Vol. 357 Issue 9268, p1576-1582. 7p.
Abstract: Background: Interferon beta reduces activity in multiple sclerosis as measured clinically and by magnetic resonance imaging (MRI). We assessed the effect of interferon beta-1a on the occurrence of relapses in patients after first presentation with neurological events, who are at high risk of conversion to clinically definite multiple sclerosis.Methods: Eligible patients had had a first episode of neurological dysfunction suggesting multiple sclerosis within the previous 3 months and had strongly suggestive brain MRI findings. Patients were randomly assigned interferon beta-1a 22 microg or placebo subcutaneously once weekly for 2 years. Neurological and clinical assessments were done every 6 months and brain MRI every 12 months. Analyses excluded one patient assigned placebo who received no study injections.Findings: 241 (78%) of 308 randomised patients received study treatment for 2 years; 278 (90%) remained in the study until termination. 57 (85%) of 67 who stopped therapy did so after conversion to clinically definite multiple sclerosis. Fewer patients developed clinically definite multiple sclerosis in the interferon group than in the placebo group (52/154 [34%] vs 69/154 [45%]; p=0.047). The time at which 30% of patients had converted to clinically definite multiple sclerosis was 569 days in the interferon group and 252 in the placebo group (p=0.034). The annual relapse rates were 0.33 and 0.43 (p=0.045). The number of new T2-weighted MRI lesions and the increase in lesion burden were significantly lower with active treatment.Interpretation: Interferon beta-1a treatment at an early stage of multiple sclerosis had significant positive effects on clinical and MRI outcomes. [ABSTRACT FROM AUTHOR]
Copyright of Lancet is the property of Lancet and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 107076624
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Comi+G%22">Comi G</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Filippi+M%22">Filippi M</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Barkhof+F%22">Barkhof F</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Durelli+L%22">Durelli L</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Edan+G%22">Edan G</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Fernández+O%22">Fernández O</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Hartung+H%22">Hartung H</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Seeldrayers+P%22">Seeldrayers P</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Sørensen+PS%22">Sørensen PS</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Rovaris+M%22">Rovaris M</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Martinelli+V%22">Martinelli V</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Hommes+OR%22">Hommes OR</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Early+Treatment+of+Multiple+Sclerosis+Study+Group%22">Early Treatment of Multiple Sclerosis Study Group</searchLink> (CORPORATE AUTHOR)<br /><searchLink fieldCode="AR" term="%22Comi%2C+G%22">Comi, G</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Filippi%2C+M%22">Filippi, M</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Barkhof%2C+F%22">Barkhof, F</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Durelli%2C+L%22">Durelli, L</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Edan%2C+G%22">Edan, G</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Fernández%2C+O%22">Fernández, O</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Hartung%2C+H%22">Hartung, H</searchLink> (AUTHOR)
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Lancet%22">Lancet</searchLink>. 5/19/2001, Vol. 357 Issue 9268, p1576-1582. 7p.
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: <bold>Background: </bold>Interferon beta reduces activity in multiple sclerosis as measured clinically and by magnetic resonance imaging (MRI). We assessed the effect of interferon beta-1a on the occurrence of relapses in patients after first presentation with neurological events, who are at high risk of conversion to clinically definite multiple sclerosis.<bold>Methods: </bold>Eligible patients had had a first episode of neurological dysfunction suggesting multiple sclerosis within the previous 3 months and had strongly suggestive brain MRI findings. Patients were randomly assigned interferon beta-1a 22 microg or placebo subcutaneously once weekly for 2 years. Neurological and clinical assessments were done every 6 months and brain MRI every 12 months. Analyses excluded one patient assigned placebo who received no study injections.<bold>Findings: </bold>241 (78%) of 308 randomised patients received study treatment for 2 years; 278 (90%) remained in the study until termination. 57 (85%) of 67 who stopped therapy did so after conversion to clinically definite multiple sclerosis. Fewer patients developed clinically definite multiple sclerosis in the interferon group than in the placebo group (52/154 [34%] vs 69/154 [45%]; p=0.047). The time at which 30% of patients had converted to clinically definite multiple sclerosis was 569 days in the interferon group and 252 in the placebo group (p=0.034). The annual relapse rates were 0.33 and 0.43 (p=0.045). The number of new T2-weighted MRI lesions and the increase in lesion burden were significantly lower with active treatment.<bold>Interpretation: </bold>Interferon beta-1a treatment at an early stage of multiple sclerosis had significant positive effects on clinical and MRI outcomes. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of Lancet is the property of Lancet and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=107076624
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/s0140-6736(00)04725-5
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 7
        StartPage: 1576
    Titles:
      – TitleFull: Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Comi G
      – PersonEntity:
          Name:
            NameFull: Filippi M
      – PersonEntity:
          Name:
            NameFull: Barkhof F
      – PersonEntity:
          Name:
            NameFull: Durelli L
      – PersonEntity:
          Name:
            NameFull: Edan G
      – PersonEntity:
          Name:
            NameFull: Fernández O
      – PersonEntity:
          Name:
            NameFull: Hartung H
      – PersonEntity:
          Name:
            NameFull: Seeldrayers P
      – PersonEntity:
          Name:
            NameFull: Sørensen PS
      – PersonEntity:
          Name:
            NameFull: Rovaris M
      – PersonEntity:
          Name:
            NameFull: Martinelli V
      – PersonEntity:
          Name:
            NameFull: Hommes OR
      – PersonEntity:
          Name:
            NameFull: Early Treatment of Multiple Sclerosis Study Group
      – PersonEntity:
          Name:
            NameFull: Comi, G
      – PersonEntity:
          Name:
            NameFull: Filippi, M
      – PersonEntity:
          Name:
            NameFull: Barkhof, F
      – PersonEntity:
          Name:
            NameFull: Durelli, L
      – PersonEntity:
          Name:
            NameFull: Edan, G
      – PersonEntity:
          Name:
            NameFull: Fernández, O
      – PersonEntity:
          Name:
            NameFull: Hartung, H
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 19
              M: 05
              Text: 5/19/2001
              Type: published
              Y: 2001
          Identifiers:
            – Type: issn-print
              Value: 01406736
          Numbering:
            – Type: volume
              Value: 357
            – Type: issue
              Value: 9268
          Titles:
            – TitleFull: Lancet
              Type: main
ResultId 1